A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Barry J. Plant; Damian G Downey; Joe A Eustace; Cedric Gunaratnam; Charles S. Haworth; Andrew M. Jones; Edward F McKone; Daniel G Peckham; R Ian Ketchell; Diana Bilton

doi:10.1016/j.jcf.2017.02.006

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Barry J. Plant, Damian G Downey, Joe A Eustace, Cedric Gunaratnam, Charles S. Haworth, Andrew M. Jones, Edward F McKone, Daniel G Peckham, R Ian Ketchell, Diana Bilton

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

354 Downloads (Pure)

Abstract

BACKGROUND: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).

METHODS: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.

RESULTS: Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).

CONCLUSIONS: In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.

Original language	English
Number of pages	7
Journal	Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Early online date	06 Apr 2017
DOIs	https://doi.org/10.1016/j.jcf.2017.02.006
Publication status	Early online date - 06 Apr 2017

Keywords

Journal Article

Access to Document

10.1016/j.jcf.2017.02.006Licence: CC BY-NC-ND

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis
© 2017 The Authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 357 KBLicence: CC BY-NC-ND

Damian Downey
- d.downeyqub.acuk
- School of Medicine, Dentistry and Biomedical Sciences - Clinical Professor
- Wellcome Wolfson Institute for Experimental Medicine
Person: Academic

Cite this

Plant, B. J., Downey, D. G., Eustace, J. A., Gunaratnam, C., Haworth, C. S., Jones, A. M., McKone, E. F., Peckham, D. G., Ketchell, R. I., & Bilton, D. (2017). A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. https://doi.org/10.1016/j.jcf.2017.02.006

Plant, Barry J. ; Downey, Damian G ; Eustace, Joe A ; Gunaratnam, Cedric ; Haworth, Charles S. ; Jones, Andrew M. ; McKone, Edward F ; Peckham, Daniel G ; Ketchell, R Ian ; Bilton, Diana. / A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. In: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2017.

@article{b092a038b2fb4470afc5001a5a3705a9,

title = "A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis",

abstract = "BACKGROUND: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).METHODS: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.RESULTS: Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).CONCLUSIONS: In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.",

keywords = "Journal Article",

author = "Plant, {Barry J.} and Downey, {Damian G} and Eustace, {Joe A} and Cedric Gunaratnam and Haworth, {Charles S.} and Jones, {Andrew M.} and McKone, {Edward F} and Peckham, {Daniel G} and Ketchell, {R Ian} and Diana Bilton",

year = "2017",

month = apr,

day = "6",

doi = "10.1016/j.jcf.2017.02.006",

language = "English",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier Inc.",

}

Plant, BJ, Downey, DG, Eustace, JA, Gunaratnam, C, Haworth, CS, Jones, AM, McKone, EF, Peckham, DG, Ketchell, RI & Bilton, D 2017, 'A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis', Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. https://doi.org/10.1016/j.jcf.2017.02.006

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. / Plant, Barry J.; Downey, Damian G; Eustace, Joe A; Gunaratnam, Cedric; Haworth, Charles S.; Jones, Andrew M.; McKone, Edward F; Peckham, Daniel G; Ketchell, R Ian; Bilton, Diana.

In: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 06.04.2017.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

AU - Plant, Barry J.

AU - Downey, Damian G

AU - Eustace, Joe A

AU - Gunaratnam, Cedric

AU - Haworth, Charles S.

AU - Jones, Andrew M.

AU - McKone, Edward F

AU - Peckham, Daniel G

AU - Ketchell, R Ian

AU - Bilton, Diana

PY - 2017/4/6

Y1 - 2017/4/6

N2 - BACKGROUND: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).METHODS: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.RESULTS: Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).CONCLUSIONS: In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.

AB - BACKGROUND: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).METHODS: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.RESULTS: Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).CONCLUSIONS: In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.

KW - Journal Article

U2 - 10.1016/j.jcf.2017.02.006

DO - 10.1016/j.jcf.2017.02.006

M3 - Article

C2 - 28392014

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

ER -

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Abstract

Keywords

Access to Document

Fingerprint

Profiles

Damian Downey

Cite this